倍他乐克对慢性心力衰竭患者肿瘤坏死因子受体Ⅱ的影响

目的探讨倍他乐克对慢性心力衰竭患者血清sTNFR—Ⅱ水平治疗前后的影响。方法采用酶联免疫双抗体夹心法测定正常对照组（26例）及慢性心力衷竭患者（60例）血清sTNFR—Ⅱ水平。其中60例心力衰竭患者随机分为常规治疗组（30例）及倍他乐克治疗组（30例），疗程4周，治疗组患者治疗前、后采血测sTNFR—Ⅱ。结果心力衰竭患者治疗前较正常对照组血清sTNFR—Ⅱ水平明显升高，差异有统计学意义（8．93±4．13）μg／L和（2．34±0．76）μg／L，P〈0．05]；心力衰竭常规治疗组及倍他乐克组治疗后血清sTNFR-Ⅱ水平均较治疗前明显降低，差异有统计学意义（8．85±5．12）μg／L和（4．38±1．76）μg儿，（9．04±4．76）μg／L和（4．67±2．15）雌儿，P〈0．05]，但两组治疗后血浆STNFR—Ⅱ水平比较差异无统计学意义（4．38±1．76）μg／L和（4．67±2．15）μg／L，P〉0．05]。结论慢性心力衰竭患者血清sTNFR—Ⅱ水平增高，倍他乐克不影响慢性心衰患者血浆sTNFR—Ⅱ水平。

Effects of Betaloc on sTNFR-Ⅱin patients with chronic heart failure

Objective To study the effects of Betaloc on sTNFR- Ⅱ in patients with chronic heart failure. Methods We measured the serum level of sTNFR- Ⅱ in 26 cases of control group and the different levels in 60 patients with chronic heart failure before and after treatment with routine drugs or Betaloc. Results The serum levels of sTNFR-Ⅱ in patients with C HF were significantly higher than those of the control group （8.93±4.13）μg/L vs （2.34±0.76）μg/L,P〈0.05 ]. After 4 weeks treatment, the serum levels of sTNFR-Ⅱ in patients with CHF were significantly decreased both in routine group and Betaloc group （8.85±5.12）μg/L vs （4.38±1.76）μg/L, （9.04± 4.76）μg/L vs （4.67±2.15）μg/L, P〈0.05 ]. Compared with the routine group, these was not a significant reduction of the serum level of sTNFR- Ⅱ in Betaloc group after treatment （4.38±1.76）μg/L vs （4.67±2.15）μg/L,P〉 0.05 ]. Conclusion The serum level of sTNFR- Ⅱ in patients with CHF was significantly high, the treatment of Betaloc could not reduce effectly the serum level of sTNFR-Ⅱ in patients with Chronic heart failure.